Tourette Syndrome

GPTKB entity

Statements (58)
Predicate Object
gptkbp:instanceOf neurological disorder
gptkbp:affects adolescents
adults
children
gptkbp:cause unknown
gptkbp:comorbidity gptkb:OCD
ADHD
learning disabilities
anxiety disorders
gptkbp:diagnosedBy gptkb:DSM-5_criteria
clinical evaluation
gptkbp:DSM-5_code 307.23
gptkbp:firstDescribed gptkb:Georges_Gilles_de_la_Tourette
1885
gptkbp:gender more common in males
gptkbp:hasNotablePerson gptkb:Chris_Jackson
gptkb:Jason_White
gptkb:Samuel_Johnson
gptkb:Dan_Aykroyd
gptkb:Michael_Wolff
gptkb:Rory_Bremner
gptkb:John_Davidson
gptkb:John_Whaite
gptkb:Dash_Mihok
gptkb:Pete_Davidson
gptkb:Tim_Howard
gptkb:Brad_Cohen
gptkb:Lele_Pons
gptkb:Jim_Eisenreich
gptkb:Scot_Pollard
gptkb:Steve_Wallace
Michael Price
Nils Eekhoff
Jessica Thom
Neal Jeffrey
Samuel Comroe
https://www.w3.org/2000/01/rdf-schema#label Tourette Syndrome
gptkbp:ICD-10_code F95.2
gptkbp:namedAfter gptkb:Georges_Gilles_de_la_Tourette
gptkbp:offersCourse can persist into adulthood
often improves in late adolescence
gptkbp:onset childhood
gptkbp:organization Tourette Association of America
Tourettes Action (UK)
European Society for the Study of Tourette Syndrome
gptkbp:prevalence about 1% of children
gptkbp:riskFactor family history
genetic factors
gptkbp:symptom motor tics
vocal tics
gptkbp:treatment gptkb:drug
behavioral therapy
antipsychotic drugs
alpha-2 adrenergic agonists
CBIT (Comprehensive Behavioral Intervention for Tics)
gptkbp:typicalOnsetAgeRange 5-10 years
gptkbp:bfsParent gptkb:Spasmodic_Movements
gptkbp:bfsLayer 6